Contraception
Volume 81, Issue 5 , Pages 408-413, May 2010

Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users☆☆☆★

  • David D. Dore

      Affiliations

    • i3 Drug Safety, Waltham, MA 02451, USA
    • Department of Community Health, The Warren Alpert Medical School of Brown University, Providence, RI 02912, USA
    • Corresponding Author InformationCorresponding author. i3 Drug Safety, Waltham, MA 02451, USA. Tel.: +1 781 472 8497; fax: +1 781 472 8464.
    • ,
  • Heather Norman

      Affiliations

    • i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • Jeanne Loughlin

      Affiliations

    • i3 Drug Safety, Waltham, MA 02451, USA
    • ,
  • John D. Seeger

      Affiliations

    • i3 Drug Safety, Waltham, MA 02451, USA
    • Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA

Received 11 November 2009; accepted 9 December 2009. published online 25 January 2010.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ This study was funded by a research contract between i3 Drug Safety and Johnson & Johnson Pharmaceutical Research & Development, LLC. The contract granted i3 Drug Safety oversight of the study conduct, reporting and interpretation, as well as final wording of any resulting manuscripts.

☆☆ An abstract (<300 words) of this paper was presented at the International Society for Pharmacoepidemiology's annual meeting in August 2009 in Providence, RI.

★ Disclosures: Dr. Dore, Ms. Norman, Ms. Loughlin and Dr. Seeger are employees of i3 Drug Safety and holders of stock and stock options in UnitedHealth Group (the parent corporation of i3 Drug Safety).

PII: S0010-7824(09)00527-7

doi:10.1016/j.contraception.2009.12.009

Contraception
Volume 81, Issue 5 , Pages 408-413, May 2010

Article Tools